クロミフェンクエン酸塩市場：適応症別、流通チャネル別、地域別-規模、シェア、展望、機会分析-2022～2028年

多嚢胞性卵巣症候群の高い発生率は、クロミフェンクエン酸塩市場の成長の主要な促進要因となると予想されます。一方で、本剤による副作用が市場の成長の妨げとなることが指摘されています。

当レポートでは、世界のクロミフェンクエン酸塩市場について調査分析し、市場の促進要因、抑制要因、市場機会、適応症・流通チャネル・地域別市場分析、企業プロファイルに関する情報を提供しています。

目次

第1章 調査目的・前提条件

第2章 市場概要

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー
  • 市場内訳：適応症別
  • 市場内訳：流通チャネル別
  • 市場内訳：地域別
• コヒーレントオポチュニティマップ（COM）

第3章 市場力学、規制、および動向分析

• 市場力学
  • 促進要因
  • 抑制要因
  • 市場機会
• 影響分析
• 市場動向
• 規制シナリオ
• 償還シナリオ
• 新製品の発売/承認
• PEST分析
• 市場でのCOVID-19の影響分析
• クロミフェンクエン酸塩の使用パターン
• 処方箋のアルゴリズムと洞察
• クロミフェンクエン酸塩の価格分析

第4章 世界のクロミフェンクエン酸塩市場：適応症別（2017～2028年（100万米ドル））

• イントロダクション
• PCOS
• 続発性無月経
• 心因性無月経
• 無月経・乳汁漏出症候群
• その他

第5章 世界のクロミフェンクエン酸塩市場：流通チャネル別（2017～2028年（100万米ドル））

• イントロダクション
• 病院薬局
• 小売薬局
• オンライン薬局

第6章 世界のクロミフェンクエン酸塩市場：地域別（2017～2028年（100万米ドル））

• イントロダクション
• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東
• アフリカ

第7章 競合情勢

• 企業プロファイル
  • Sanofi SA
  • Par Pharmaceutical
  • Merck & Co. Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Cipla Inc.
  • Unichem Laboratories Ltd.
  • Emcure Pharmaceuticals Ltd.
  • Serum Institute of India Pvt. Ltd.
  • Incepta Pharmaceuticals Ltd.
  • Shanghai Trifecta Pharma Co. Ltd.

第8章 セクション

According to the data published in the National Institutes of Health (NIH) in January 2017, the most common overall cause of female infertility is the failure to ovulate, which occurs in 40% of women with infertility issues, globally. To treat such infertility problems in females, clomiphene citrate is the first choice of medicine for the past 40 years, according to the Global Library of Women's Medicine. Gynecologists prescribe clomiphene for 1 to 6 months or more with a low dose of 50 mg daily (1 tablet) for 5 days. If ovulation does not occur after the first course of therapy, a second course of 100 mg daily (two 50 mg tablets given as a single daily dose) for 5 days is prescribed.

According to a study called 'Clomiphene citrate usage pattern in India' conducted by Fertility Science and Research in 2014, ovulation rate was reported to increase from 21% to 60% and the pregnancy rate was noticed to be increased by 11% to 30% by majority of participants. The ovulation rate and pregnancy rate was increased using clomiphene citrate because of increased secretion of hypothalamic gonadotropin-releasing hormone (GnRH) to increase the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which will, in turn, stimulate ovarian follicular activity.

Market Dynamics

High incidence of polycystic ovarian syndrome is expected to be a key driver for the clomiphene citrate market growth. For instance, according to an article published in 2014 in Clinical Epidemiology, polycystic ovarian syndrome affects 8% to 20% of the reproductive-age women, globally. According to the World Health Organization, in 2012, polycystic ovarian syndrome affected 116 million women, worldwide.

The clomiphene citrate market growth is hindered by side effects shown by this drug, which includes headache, nausea, upper respiratory tract infection, abdominal tenderness, sinus congestion, mood swings, acne, breast tenderness, weight gain, pelvic discomfort, abnormal bleeding or spotting, vomiting, injection site pain, redness, dizziness, and ovarian hyper-stimulation syndrome (OHSS). For instance, according to a study published in NCBI, in 2016, 10% to 20% of women who consumed clomiphene citrate developed a mild form of OHSS, which will usually resolve on its own. Severe cases of OHSS occurred in less than one percent of patients in the U.S.

Key features of the study:

• This report provides in-depth analysis of the global clomiphene citrate market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
• It profiles key players in the global clomiphene citrate market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
• Key players covered as a part of this study include Sanofi S.A., Par Pharmaceutical, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Cipla Inc., Unichem Laboratories Ltd., Emcure Pharmaceuticals Ltd., Serum Institute of India Pvt. Ltd., Incepta Pharmaceuticals Ltd., and Shanghai Trifecta Pharma Co. Ltd.
• Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
• The global clomiphene citrate market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for clomiphene citrate market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

• Global Clomiphene Citrate Market, By Indication:
  • PCOS
  • Secondary Amenorrhea
  • Psychogenic Amenorrhea
  • Amenorrhea Galactorrhea Syndrome
  • Others
• Global Clomiphene Citrate Market, By Distribution Channel::
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Clomiphene Citrate Market, By Region:
  • North America
    • By Country:
  • U.S.
  • Canada
    • By Indication:
  • PCOS
  • Secondary Amenorrhea
  • Psychogenic Amenorrhea
  • Amenorrhea Galactorrhea Syndrome
  • Others
    • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Europe
    • By Country:
  • U.K.
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe
    • By Indication:
  • PCOS
  • Secondary Amenorrhea
  • Psychogenic Amenorrhea
  • Amenorrhea Galactorrhea Syndrome
  • Others
    • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Asia Pacific
    • By Country:
  • Australia
  • India
  • China
  • Japan
  • ASEAN
  • South Korea
  • Rest of Asia Pacific
    • By Indication:
  • PCOS
  • Secondary Amenorrhea
  • Psychogenic Amenorrhea
  • Amenorrhea Galactorrhea Syndrome
  • Others
    • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Latin America
    • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
    • By Indication:
  • PCOS
  • Secondary Amenorrhea
  • Psychogenic Amenorrhea
  • Amenorrhea Galactorrhea Syndrome
  • Others
    • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Middle East
    • By Country:
  • GCC
  • Israel
  • Rest of Middle East
    • By Indication:
  • PCOS
  • Secondary Amenorrhea
  • Psychogenic Amenorrhea
  • Amenorrhea Galactorrhea Syndrome
  • Others
    • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Africa
    • By Country/Region:
  • South Africa
  • Central Africa
  • North Africa
    • By Indication:
  • PCOS
  • Secondary Amenorrhea
  • Psychogenic Amenorrhea
  • Amenorrhea Galactorrhea Syndrome
  • Others
    • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Company Profiles
  • Sanofi S.A.*
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Par Pharmaceutical
  • Merck & Co. Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Cipla Inc.
  • Unichem Laboratories Ltd.
  • Emcure Pharmaceuticals Ltd.
  • Serum Institute of India Pvt. Ltd.
  • Incepta Pharmaceuticals Ltd.
  • Shanghai Trifecta Pharma Co. Ltd.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Overview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Indication
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Regulatory Scenario
• Reimbursement Scenario
• New Product Launches/Approvals
• PEST Analysis
• Impact Analysis of COVID-19 On Market
• Clomiphene Citrate Usage Pattern
• Prescription Algorithm And Insights
• Pricing Analysis of Clomiphene Citrate

4. Global Clomiphene Citrate Market, By Indication, 2017 - 2028, (US$ Million)

• Introduction
  • Market Share Analysis, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
• PCOS
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Secondary Amenorrhea
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Psychogenic Amenorrhea
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Amenorrhea Galactorrhea Syndrome
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

5. Global Clomiphene Citrate Market, By Distribution Channel, 2017 - 2028, (US$ Million)

• Introduction
  • Market Share Analysis, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

6. Global Clomiphene Citrate Market, By Region, 2017 - 2028, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, By Region, 2017 - 2028
  • Regional Trends
• North America
  • Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
  • U.S.
  • Canada
• Europe
  • Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East
  • Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Country/Region, 2017 - 2028, (US$ Million)
  • North Africa
  • Central Africa
  • South Africa

7. Competitive Landscape

• Company Profiles
  • Sanofi S.A.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Par Pharmaceutical
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Merck & Co. Inc.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Cipla Inc.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Unichem Laboratories Ltd.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Emcure Pharmaceuticals Ltd.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Serum Institute of India Pvt. Ltd.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Incepta Pharmaceuticals Ltd.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Shanghai Trifecta Pharma Co. Ltd.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies

8. Section

• References
• Research Methodology
• About us and Sales Contact